miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype

An,Feng; Liu,Yidong; Hu,Yan

doi:10.3892/ol.2017.6746

miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype

Authors:
- Feng An
- Yidong Liu
- Yan Hu
View Affiliations

Affiliations: Department of Urinary Surgery, Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China, Department of Urinary Surgery, Taian City Central Hospital, Taian, Shandong 271000, P.R. China
Published online on: August 10, 2017 https://doi.org/10.3892/ol.2017.6746
Pages: 4684-4688
Copyright: © An et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)-21 has many regulatory functions in the cell, including activities in cancer cells and cancer stem cells. Large tumor suppressor gene 1 (LATS1) is a target of miR‑21 that could mediate several of these phenotypes. This study explored the effect of miR‑21 silencing in renal cancer cell function and LATS1 expression. Silencing of miR‑21 in Caki‑2 cells reached an efficiency of 55‑60%. This was sufficient to detect decrease in Caki‑2 cell proliferation and migration invasion capacity. miR‑21 silencing increased LATS1 expression at both mRNA and protein levels. The number of tumor spheres formed by cells expressing si‑miR‑21 was significantly reduced and the expression of tumor stem cell markers Nanog and CT3/4 were significantly downregulated. miR‑21 seems to regulate LATS1 expression in renal cancer Caki‑2 cells, resulting in reduced proliferation, invasion, and cancer stem cell phenotype. miR‑21 may promote malignant phenotype of tumor cells through LATS1 silencing, which can be regarded as a new target candidate gene for renal cancer treatment.

View Figures

View References

1	Creighton CJ, Morgan M, Gunaratne PH, Wheeler DA, Gibbs RA, Robertson Gordon A, Chu A, Beroukhim R, Cibulskis K, Signoretti S, et al: Cancer Genome Atlas Research Network: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
2	Junker K, Ficarra V, Kwon ED, Leibovich BC, Thompson RH and Oosterwijk E: Potential role of genetic markers in the management of kidney cancer. Eur Urol. 63:333–340. 2013. View Article : Google Scholar : PubMed/NCBI
3	Silahtaroglu A and Stenvang J: MicroRNAs, epigenetics and disease. Essays Biochem. 48:165–185. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ross SA and Davis CD: MicroRNA, nutrition, and cancer prevention. Adv Nutr. 2:472–485. 2011. View Article : Google Scholar : PubMed/NCBI
5	Nimmo RA and Slack FJ: An elegant miRror: microRNAs in stem cells, developmental timing and cancer. Chromosoma. 118:405–418. 2009. View Article : Google Scholar : PubMed/NCBI
6	Chan JA, Krichevsky AM and Kosik KS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI
7	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
8	Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, Yang J, Paun B, Jin Z, Agarwal R, et al: MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 49:1595–1601. 2009. View Article : Google Scholar : PubMed/NCBI
9	Dillhoff M, Liu J, Frankel W, Croce C and Bloomston M: MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg. 12:2171–2176. 2008. View Article : Google Scholar : PubMed/NCBI
10	Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, Alattar M, Deepak J, Stass SA and Jiang F: Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer. 67:170–176. 2010. View Article : Google Scholar : PubMed/NCBI
11	Rossi L, Bonmassar E and Faraoni I: Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res. 56:248–253. 2007. View Article : Google Scholar : PubMed/NCBI
12	Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, Patel S, Phung NA, McLaughlin S, Libertino JA, Whitney D, et al: A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol. 28:39–48. 2010. View Article : Google Scholar : PubMed/NCBI
13	Lv L, Huang F, Mao H, Li M, Li X, Yang M and Yu X: MicroRNA-21 is overexpressed in renal cell carcinoma. Int J Biol Markers. 28:201–207. 2013. View Article : Google Scholar : PubMed/NCBI
14	Feber A, Xi L, Luketich JD, Pennathur A, Landreneau RJ, Wu M, Swanson SJ, Godfrey TE and Litle VR: MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg. 135:255–260; discussion 260. 2008. View Article : Google Scholar : PubMed/NCBI
15	Mo JS, Park HW and Guan KL: The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 15:642–656. 2014.PubMed/NCBI
16	Harvey K and Tapon N: The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer. 7:182–191. 2007. View Article : Google Scholar : PubMed/NCBI
17	Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G and Lu D: Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res. 56:450–458. 2006. View Article : Google Scholar : PubMed/NCBI
18	Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y and Noguchi S: Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res. 11:1380–1385. 2005. View Article : Google Scholar : PubMed/NCBI
19	Steinmann K, Sandner A, Schagdarsurengin U and Dammann RH: Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep. 22:1519–1526. 2009.PubMed/NCBI
20	Wierzbicki PM, Adrych K, Kartanowicz D, Stanislawowski M, Kowalczyk A, Godlewski J, Skwierz-Bogdanska I, Celinski K, Gach T, Kulig J, et al: Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation. World J Gastroenterol. 19:4363–4373. 2013. View Article : Google Scholar : PubMed/NCBI
21	Visser S and Yang X: Identification of LATS transcriptional targets in HeLa cells using whole human genome oligonucleotide microarray. Gene. 449:22–29. 2010. View Article : Google Scholar : PubMed/NCBI
22	Zhou GX, Li XY, Zhang Q, Zhao K, Zhang CP, Xue CH, Yang K and Tian ZB: Effects of the hippo signaling pathway in human gastric cancer. Asian Pac J Cancer Prev. 14:5199–5205. 2013. View Article : Google Scholar : PubMed/NCBI
23	Nishio M, Hamada K, Kawahara K, Sasaki M, Noguchi F, Chiba S, Mizuno K, Suzuki SO, Dong Y, Tokuda M, et al: Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice. J Clin Invest. 122:4505–4518. 2012. View Article : Google Scholar : PubMed/NCBI
24	Zhao B, Li L, Wang L, Wang CY, Yu J and Guan KL: Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 26:54–68. 2012. View Article : Google Scholar : PubMed/NCBI
25	Chen KH, He J, Wang DL, Cao JJ, Li MC, Zhao XM, Sheng X, Li WB and Liu WJ: Effects of LATS1 gene methylation on biological function in human renal cell carcinoma and Hippo-YAP signaling pathway. J Third Mil Med Univ. 36:1249–1254. 2014.
26	Liu S, Song L, Zhang L, Zeng S and Gao F: miR-21 modulates resistance of HR-HPV positive cervical cancer cells to radiation through targeting LATS1. Biochem Biophys Res Commun. 459:679–685. 2015. View Article : Google Scholar : PubMed/NCBI
27	Teteloshvili N, Smigielska-Czepiel K, Yuan Y, Seitz A, de Jong D, Rutgers B, Jellema P, van der Lei RJ, Slezak-Prochazka I, Brouwer E, et al: Argonaute 2 immunoprecipitation revealed large tumor suppressor kinase 1 as a novel proapoptotic target of miR-21 in T cells. FEBS J. 284:555–567. 2017. View Article : Google Scholar : PubMed/NCBI
28	Liu S, Song L, Zhang L, Zeng S and Gao F: miR-21 modulates resistance of HR-HPV positive cervical cancer cells to radiation through targeting LATS1. Biochem Biophys Res Commun. 459:679–685. 2015. View Article : Google Scholar : PubMed/NCBI
29	Xia H, Qi H, Li Y, Pei J, Barton J, Blackstad M, Xu T and Tao W: LATS1 tumor suppressor regulates G2/M transition and apoptosis. Oncogene. 21:1233–1241. 2002. View Article : Google Scholar : PubMed/NCBI
30	Chen J and Wang X: MicroRNA-21 in breast cancer: Diagnostic and prognostic potential. Clin Transl Oncol. 16:225–233. 2014. View Article : Google Scholar : PubMed/NCBI